<DOC>
	<DOCNO>NCT03100916</DOCNO>
	<brief_summary>The primary objective trial investigate safety tolerability BI 690517 healthy male subject follow oral administration multiple rise dos 14 day ( MRD part ) . Secondary objective MRD part exploration PK ( Pharmacokinetic ( ) ) , include dose proportionality , well investigation linearity PD ( Pharmacodynamic ( ) ) BI 690517 multiple dosing . For FE ( food effect ) part , secondary objective investigate relative bioavailability BI 690517 fast condition ( Reference , R ) compare BI 690517 ( single dose ) high fat high caloric breakfast ( Test , T ) .</brief_summary>
	<brief_title>This Study Tests How Different Doses BI 690517 Are Taken Body Healthy Men . The Study Also Looks How Food Influences Amount BI 690517 Blood</brief_title>
	<detailed_description />
	<criteria>Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP ( Blood Pressure ) , PR ( Pulse Rate ) ) , 12lead ECG ( Electrocardiogram ) , clinical laboratory test Age 18 50 year ( incl . ) BMI ( Body Mass Index ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Willingness comply contraception requirement . Subjects sexually active must use adequate contraception female partner throughout study one month last administration trial medication . Adequate method : Sexual abstinence A vasectomy perform least 1 year prior screen combination barrier method ( condom ) Surgical sterilisation ( include bilateral tubal occlusion , hysterectomy bilateral oophorectomy ) subject 's female partner The use condom , female partner use adequate contraception method addition , e.g. , intrauterine device ( IUD ) , hormonal contraception ( e.g . implant , injectables , combine oral vaginal contraceptive ) start least 2 month prior first drug administration , barrier method ( e.g . diaphragm spermicide ) Unprotected sexual intercourse female partner allow throughout study one month last administration trial medication . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout ; orthostatic dysregulation identify screening Day 1 ) Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalaemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Values serum sodium potassium outside normal range screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>